Study guide

14.3 Rapidly Progressive Glomerulonephritis

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

14.3 Rapidly Progressive Glomerulonephritis

Key Takeaways Explain This Topic AI

Anti-GBM (Goodpasture) disease shows linear IgG staining on immunofluorescence and is treated with plasma exchange, corticosteroids and cyclophosphamide.

Pauci-immune crescentic glomerulonephritis is ANCA-associated, with PR3-ANCA in granulomatosis with polyangiitis and MPO-ANCA in microscopic polyangiitis.

Pulmonary-renal syndrome should prompt urgent testing for anti-GBM antibodies and ANCA in parallel, since both can present with haemoptysis and acute kidney injury.

Last updated: September 2026

3. Rapidly Progressive Glomerulonephritis (RPGN / Crescentic GN)

RPGN is a clinical syndrome characterized by a rapid loss of renal function (frequently a doubling of serum creatinine within days to weeks) accompanied by an active nephritic sediment and pathologically defined by extensive crescent formation in > 50% of glomeruli on renal biopsy.

Crescent Pathophysiology

Severe transmural necrosis of glomerular capillary walls leads to extravasation of fibrin, inflammatory cytokines, tissue factor, and red blood cells directly into Bowman's space. This triggers rapid proliferation of parietal epithelial cells and recruitment of circulating monocytes and T-lymphocytes, forming multiple layers of cells ( cellular crescents ) that compress the glomerular tuft. Left untreated, cellular crescents organize into irreversible fibrous scars. RPGN Classification (by Immunofluorescence)

  • |
  • +----------------------------------------+----------------------------------------+
  • | | |
  • Type I Type II Type III
  • (Anti-GBM Disease) (Immune-Complex Mediated) (Pauci-Immune AAV)
  • | | |
  • Linear IgG on IF Granular IgG/C3 on IF Negative / Scant IF
  • Auto-Ab to alpha-3(IV)NC1 - Lupus Nephritis (Full House) - GPA (PR3-ANCA / c-ANCA)
  • Goodpasture Syndrome: - Cryoglobulinaemia (HCV, low C4) - MPA (MPO-ANCA / p-ANCA)
  • Pulmonary Haemorrhage + GN - Post-infectious GN / IgA - EGPA (eosinophilia, asthma)
  • Emergency Plasmapheresis Pulsed Steroids + MMF / Cyclo Pulsed Steroids + Rituximab
  • Type I: Anti-GBM Disease & Goodpasture's Syndrome

Immunology: Autoantibodies directed against the non-collagenous domain 1 of the alpha-3 chain of type IV collagen [alpha-3(IV)NC1]. When associated with necrotizing pulmonary alveolar haemorrhage (presenting with dyspnoea, haemoptysis, iron-deficiency anaemia, bilateral diffuse alveolar infiltrates, and increased carbon monoxide gas transfer KCO), it is termed Goodpasture's syndrome .

Immunofluorescence: Diagnostic, pathognomonic continuous smooth linear IgG (and C3) deposition along the entire glomerular basement membrane.

Management: Medical emergency! Requires immediate daily plasma exchange (plasmapheresis) for 14 days (or until circulating anti-GBM antibodies become undetectable) to physically remove circulating pathogenic IgG, combined with high-dose intravenous pulsed methylprednisolone followed by oral prednisolone, and oral cyclophosphamide . Dialysis-dependent patients with 100% crescents at presentation have a dismal renal prognosis.

Type II: Immune-Complex Mediated Crescentic GN

Systemic Lupus Erythematosus (Lupus Nephritis): Categorized by the ISN/RPS classification into classes I through VI. Class IV (Diffuse Proliferative Lupus Nephritis) is the most aggressive, characterized by extensive subendothelial immune deposits producing "wire-loop" lesions on LM. IF reveals pathognomonic "full-house" staining (simultaneous granular positivity for IgG, IgA, IgM, C3, and C1q). Serology demonstrates high-titre anti-dsDNA and profound hypocomplementaemia (both low C3 and low C4). Induction therapy comprises intravenous pulsed methylprednisolone combined with either mycophenolate mofetil (MMF) or intravenous cyclophosphamide (Euro-Lupus regimen), often with belimumab.

Cryoglobulinaemic Glomerulonephritis: Mixed cryoglobulinaemia (Types II and III) containing monoclonal IgM with rheumatoid factor activity directed against polyclonal IgG. Strongly associated with chronic Hepatitis C virus (HCV) infection. Presents with Meltzer's triad (palpable purpura, arthralgias, weakness) and membranoproliferative GN. Serology reveals markedly depressed C4 (characteristically undetectable, with near-normal C3), positive rheumatoid factor, and detectable HCV RNA. Managed with direct-acting antivirals (DAAs), rituximab, and plasma exchange for severe flares.

Type III: Pauci-Immune ANCA-Associated Vasculitis (AAV)

Characterized on renal biopsy by necrotizing crescentic glomerulonephritis with scant or absent immunoglobulin/complement deposition ("pauci-immune") on immunofluorescence.

Granulomatosis with Polyangiitis (GPA, formerly Wegener's): Systemic necrotizing granulomatous vasculitis. Manifests with upper respiratory tract involvement (chronic sinusitis, epistaxis, nasal crusting, saddle-nose deformity , subglottic stenosis), pulmonary cavitating nodules or alveolar haemorrhage, and necrotizing crescentic GN. Strongly associated with c-ANCA (cytoplasmic) directed against Proteinase 3 (PR3-ANCA) in > 90% of cases.

Microscopic Polyangiitis (MPA): Non-granulomatous small-vessel vasculitis causing pulmonary-renal syndrome (alveolar haemorrhage and rapidly progressive GN) without destructive upper respiratory granulomatous disease. Strongly associated with p-ANCA (perinuclear) directed against Myeloperoxidase (MPO-ANCA) in > 75–85% of cases.

Eosinophilic Granulomatosis with Polyangiitis (EGPA, Churg-Strauss): Severe late-onset asthma, peripheral eosinophilia, transient pulmonary infiltrates, mononeuritis multiplex, and p-ANCA/MPO positivity in 40–50%.

Management of Severe AAV: High-dose pulsed intravenous methylprednisolone followed by oral prednisolone plus rituximab (or intravenous cyclophosphamide) for remission induction. The oral C5a receptor antagonist avacopan allows significant steroid reduction (ADVOCATE trial). Maintenance is achieved with rituximab or azathioprine.

Investigation Sequence

Time is nephrons. The moment crescentic disease is suspected — a rising creatinine over days with dysmorphic red cells and red cell casts on urine microscopy — send the immunological screen in parallel rather than in sequence :

  • Test What a positive result indicates
  • Anti-GBM antibody Type I: anti-glomerular basement membrane (Goodpasture) disease
  • ANCA with PR3 and MPO specificity Type III: pauci-immune ANCA-associated vasculitis
  • ANA, anti-dsDNA, C3 and C4 Type II: immune complex disease, especially lupus nephritis
  • ASO titre / anti-DNase B Post-streptococcal glomerulonephritis
  • Cryoglobulins, hepatitis B and C serology Cryoglobulinaemic glomerulonephritis
  • Serum free light chains, immunoglobulins Myeloma-related renal disease as a mimic

A low C3 with low C4 points to immune complex disease (lupus, cryoglobulinaemia, endocarditis-associated); a low C3 with normal C4 points to post-streptococcal disease or C3 glomerulopathy; normal complement is typical of pauci-immune and anti-GBM disease. Renal biopsy is the definitive investigation and should be arranged urgently, but treatment must not wait for histology in a rapidly deteriorating patient.

Immunosuppressive Protocols

Induction for organ-threatening disease is high-dose corticosteroid (often intravenous methylprednisolone) plus either rituximab or cyclophosphamide , followed by maintenance with rituximab or azathioprine. Plasma exchange is standard and urgent in anti-GBM disease , where it removes circulating antibody, and remains the treatment of choice in the patient with pulmonary haemorrhage. In ANCA-associated vasculitis the PEXIVAS trial showed no overall benefit of routine plasma exchange on death or end-stage renal disease, so its use is now restricted to selected severe presentations — a genuine change from older teaching that examiners are alert to.

Prognosis and Pitfalls

Patients with anti-GBM disease who are dialysis-dependent at presentation with 100% crescents rarely recover renal function , though pulmonary haemorrhage still justifies plasma exchange.

Anti-GBM disease shows a strong association with HLA-DRB1*15:01 , and smoking or hydrocarbon exposure precipitates the pulmonary component.

Roughly a third of patients with anti-GBM disease are also ANCA positive (usually MPO), the so-called double-positive group, which relapses like vasculitis and needs prolonged maintenance.

All patients on cyclophosphamide or rituximab require Pneumocystis jirovecii prophylaxis with co-trimoxazole and bone protection.